Pages and pages of references supporting this that your doctor will also be conversant in. Don't bother asking any questions about points in here, that would be questioning your doctors' competence. You would hate to hurt their fee fees.
http://journal.frontiersin.org/article/10.3389/fnins.2015.00458/full?
- GIGA-Neurosciences, University of Liege, C.H.U. Sart Tilman, Liege, Belgium
Introduction
Stroke is the second leading cause of death, the most
common cause of adult-acquired disability and affects one in every six
people worldwide (Moskowitz et al., 2010).
The number of people who survive a stroke is increasing, and with an
aging population, the incidence and prevalence of stroke are predicted
to rise even more (Sun et al., 2012).
Despite years of research, effective treatments remain elusive.
Currently, the only proven therapy for acute ischemic stroke is systemic
thrombolysis with recombinant tissue plasminogen activator (rtPA). To
be effective, rtPA must be administered within a maximum of 4.5 h after
the symptoms first start. This short timeframe and potential adverse
effects have limited the use of rtPA to 3–5% of stroke patients (Ruan et al., 2015).
Grafting stem cells represents a compelling alternative and offers both
a wide array and an unlimited supply of cells. Indeed, the
transplantation of neural stem cells (NSCs), mesenchymal stem cells
(MSCs), embryonic stem cells (ESCs), or induced pluripotent stem cells
(iPSCs) could be used to replace neuronal loss after stroke (Kalladka and Muir, 2014).
However, exogenous stem cell therapy has both technical and ethical
issues. For instance, cell survival and migration rely heavily on the
timing and mode of delivery (Li et al., 2010; Darsalia et al., 2011). Moreover, surgical procedure and toxicity (as cancer induction) increase the complexity of transplanted cell therapies (Kawai et al., 2010; Ben-David and Benvenisty, 2011). Finally, some ethical issues may arise from the use of fetal/embryonic cells.
Despite the fact that the central nervous system (CNS) has a limited repair capacity (Nakagomi et al., 2011), some degree of spontaneous recovery from brain ischemia invariably occurs (Yu et al., 2014).
This repair process involves neurogenesis, angiogenesis, and axonal
sprouting and synaptogenesis. Here we concentrate on the events that are
associated with the production of new neurons and not the mechanisms
that involve the reorganization of connectivity among surviving neurons,
which is reviewed elsewhere (Jones and Adkins, 2015).
Recent experimental findings have raised the possibility
that functional improvement after stroke may be induced through
neuronal replacement by endogenous NSCs. Indeed, the original dogma that
no new neurons are formed after birth has been definitively overturned
during the past few decades. The discovery of the thymidine analog
bromodeoxyuridine (BrdU)—that incorporates into DNA in S-phase and can
be detected by immunohistochemistry—has allowed researchers to
conclusively demonstrate the generation of new neurons in the brain of
all adult mammals including humans (Eriksson et al., 1998; Gage, 2000).
This production of new neurons in the adult brain—so-called adult
neurogenesis—takes place in areas called neurogenic niches. The
subventricular zone (SVZ) of the lateral ventricle and the subgranular
zone (SGZ) of the dentate gyrus (DG) are the two main neurogenic niches
containing adult NSCs that proliferate, divide and differentiate into
mature neurons. Recently, new evidence have highlighted that adult
neurogenesis could also takes place in other brain areas, along the
ventricular system, mostly in pathological conditions (Lin and Iacovitti, 2015).
The capacity to produce new neurons in the adult brain
and the ability of the ischemia-injured adult brain to partially recover
suggest a possible relationship between adult neurogenesis and stroke
recovery. Indeed, many studies have shown an increase in cell
proliferation in the rodent SVZ following ischemic injury (Thored et al., 2006), and evidence for stroke-induced neurogenesis in the human brain has also been reported (Jin et al., 2006).
In addition, endogenous brain repair is not limited to neurogenic
niches. Recent studies have shown that glial cells surrounding the
infarct core can be reactivated following ischemia. Indeed, pericytes,
oligodendrocyte precursors, and astrocytes are all able to differentiate
into neurons following brain injury (Robel et al., 2011; Heinrich et al., 2014; Nakagomi et al., 2015; Torper et al., 2015).
Moreover, surviving neurons may reorganize their connections in a
manner that supports some degree of spontaneous improvement. Therefore, a
promising field of investigation is focused on triggering and
stimulating this self-repair system to replace dead neurons following an
ischemic attack.
No comments:
Post a Comment